DISCLAIMER: This page is intended for members of the general public in Taiwan only.
The information provided on this site is intended for general information and education for Taiwan-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has granted emergency use authorization by the Taiwan Food and Drug Administration for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Important information
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
If you are concerned about any potential side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the Package Leaflet.
Either you or your healthcare professional can report any suspected adverse reactions via the national reporting system of Taiwan at https://www.fda.gov.tw/ENG/lawContent.aspx?cid=5063&id=3357.